Exosome service company

Extracellular vesicles (EVs) or exosomes are subcellular entities released by cells. It is becoming widely known that exosomes are as effective as cell therapies for tissue regeneration for diseases such as stroke, heart failure, arthritis while being safer and more convenient for supply chains. Therefore, they could be a key asset to the future health of an ageing population and are increasingly explored by many stakeholders.

However, the ability to manufacture quantities of exosomes compatible with human use is a major challenge for the diffusion of this innovation. Indeed, the major hindrance to overcome for rendering exosome-based therapies clinically feasible is a cost-effective large-scale standardized production platform complying with regulatory issues and Good Manufacturing Practices (GMP). Existing production methods gives low manufacturing yields, are not all scalable and are very time consuming, rarely GMP compliant, making clinical translation of exosome-based therapeutics very difficult.

With its breakthrough technology, EVerZom is adressing this challenge and works towards the democratization of exosome-based-therapies.